This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Linsidomine
- DrugBank Accession Number
- DB13400
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Linsidomine (DB13400)
- Weight
- Average: 170.172
Monoisotopic: 170.080375578 - Chemical Formula
- C6H10N4O2
- Synonyms
- Linsidomina
- Linsidomine
- Linsidominum
- External IDs
- CV 664
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Linsidomine. Abciximab The risk or severity of bleeding can be increased when Linsidomine is combined with Abciximab. Abrocitinib The risk or severity of bleeding and thrombocytopenia can be increased when Linsidomine is combined with Abrocitinib. Acebutolol Acebutolol may increase the hypotensive activities of Linsidomine. Aceclofenac The risk or severity of bleeding can be increased when Aceclofenac is combined with Linsidomine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Linsidomine hydrochloride Y0054U597M 16142-27-1 ZRFWHHCXSSACAW-UHFFFAOYSA-M
Categories
- ATC Codes
- C01DX18 — Linsidomine
- Drug Categories
- Antihypertensive Agents
- Antiplatelet agents
- Cardiac Therapy
- Cardiovascular Agents
- Enzyme Inhibitors
- Hematologic Agents
- Morpholines
- Nitric Oxide Donors
- Oxadiazoles
- Oxazines
- Oxazoles
- Sodium-Potassium-Exchanging ATPase, antagonists & inhibitors
- Sydnones
- Vasodilating Agents
- Vasodilators Used in Cardiac Diseases
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Oxazinanes
- Sub Class
- Morpholines
- Direct Parent
- Morpholines
- Alternative Parents
- Heteroaromatic compounds / 1,2,3-oxadiazoles / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- 1,2,3-oxadiazole / Aromatic heteromonocyclic compound / Azacycle / Azole / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Morpholine / Organic nitrogen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5O5U71P6VQ
- CAS number
- 33876-97-0
- InChI Key
- FKDHHVKWGRFRTG-UHFFFAOYSA-N
- InChI
- InChI=1S/C6H10N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7H,1-4H2
- IUPAC Name
- 5-azanidyl-3-(morpholin-4-yl)-1,2,3lambda5-oxadiazol-3-ylium
- SMILES
- [NH-]C1=C[N+](=NO1)N1CCOCC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 10561427
- BindingDB
- 83470
- ChEBI
- 136004
- ChEMBL
- CHEMBL1189150
- Wikipedia
- Linsidomine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 31.2 mg/mL ALOGPS logP -1.2 ALOGPS logP -2.1 Chemaxon logS -0.86 ALOGPS pKa (Strongest Acidic) 10.06 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 62.61 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 60.32 m3·mol-1 Chemaxon Polarizability 16.29 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-002o-9400000000-97e8a967ce482ba7db8a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 133.5679 predictedDeepCCS 1.0 (2019) [M+H]+ 135.96349 predictedDeepCCS 1.0 (2019) [M+Na]+ 142.85878 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:41 / Updated at February 21, 2021 18:54